Regulatory Outlook finally claims FDA approval for AMD drug PharmaphorumAfter three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.OphthalmologyRead full story pharminent July 27, 2026 (Last updated: July 27, 2026) Pharmaphorum After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US. Ophthalmology Read full story Post navigation Previous: Outlook Therapeutics wins FDA approval for Lytenava in wet AMDNext: Argenx deepens immuno expertise with $2.2B Forte Biosciences buy Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026